• Explore /
  • Poster
  • / Evolve: A post PARP inhibitor clinical translational Phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.

Evolve: A post PARP inhibitor clinical translational Phase II trial of cediranib-olaparib in ovarian cancer—A Princess Margaret Consortium – GCIG Phase II Trial.

Abstract Poster

Authors

null

Stephanie Lheureux

University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada

Stephanie Lheureux , Ana Oaknin , Swati Garg , Jeffrey Bruce , Neesha C. Dhani , Ainhoa Madariaga , Luisa Bonilla , Yeh Chen Lee , Ilaria Colombo , Gita Bhat , Valerie Bowering , Justin White , Sarah Accardi , Susie Tan , Marsela Braunstein , Katherine Karakasis , Zhihui (Amy) Liu , Trevor John Pugh , Amit M. Oza

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT02681237

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5521)

DOI

10.1200/JCO.2019.37.15_suppl.5521

Abstract #

5521

Poster Bd #

344

Abstract Disclosures

Similar Posters

First Author: Joseph W. Kim

First Author: Helen Mackay

First Author: Joyce F. Liu

First Author: Joyce F. Liu